<DOC>
	<DOCNO>NCT01742611</DOCNO>
	<brief_summary>This multi-center , open-labeled , non-comparative study examine safety efficacy ASP1585 long-term dosing chronic kidney disease patient hyperphosphatemia dialysis .</brief_summary>
	<brief_title>Long-term Study Chronic Kidney Disease Patients With Hyperphosphatemia Not Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<criteria>Patients complete study 1585CL0101 new patient meet follow criterion Chronic kidney disease patient ( eGFR &lt; 60 mL/min/1.73 m2 ) Serum phosphorus measurement â‰§4.6 mg/dl , &lt; 9.0 mg/dl Written inform consent Patients gastrointestinal surgery enterectomy Patients severe cardiac disease Patients severe constipation diarrhea Patients history complication malignant tumor Patients uncontrolled hypertension Patients treat parathyroid intervention</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>CKD</keyword>
	<keyword>Not dialysis</keyword>
	<keyword>ASP1585</keyword>
	<keyword>Bixalomer</keyword>
</DOC>